Compare PCRX & CTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | CTO |
|---|---|---|
| Founded | 2006 | 1902 |
| Country | United States | United States |
| Employees | N/A | 42 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 599.1M |
| IPO Year | 2010 | N/A |
| Metric | PCRX | CTO |
|---|---|---|
| Price | $22.72 | $19.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $37.20 | $21.50 |
| AVG Volume (30 Days) | ★ 579.3K | 177.5K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 8.00% |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $6.78 | $7.63 |
| Revenue Next Year | $8.54 | $2.76 |
| P/E Ratio | $139.00 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $15.07 |
| 52 Week High | $27.99 | $20.25 |
| Indicator | PCRX | CTO |
|---|---|---|
| Relative Strength Index (RSI) | 50.23 | 57.54 |
| Support Level | $22.57 | $17.14 |
| Resistance Level | $23.94 | $19.82 |
| Average True Range (ATR) | 0.79 | 0.33 |
| MACD | -0.06 | 0.05 |
| Stochastic Oscillator | 53.31 | 91.54 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.